Analysis of in vivo mutation data can inform cancer risk assessment

Regulatory Toxicology and Pharmacology

Volumn 51, Issue 2, 2008, Pages 151-161

  Moore, Martha M ^a   Heflich, Robert H ^a   Haber, Lynne T ^b   Allen, Bruce C ^c   Shipp, Annette M ^d   Kodell, Ralph L ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Toxicology Excellence for Risk Assessment   (United States)

^c Bruce Allen Consulting   (United States)

^d ENVIRON Health Sciences Institute   (United States)

Author keywords

Cancer risk assessment; Mode of action; Mutagenic carcinogen; Nonmutagenic carcinogen

Indexed keywords

CARCINOGEN; DICHLOROACETIC ACID; PYRROLIZIDINE ALKALOID; RIDDELLINE;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DOSE RESPONSE; EXPERIMENTAL DESIGN; GENE MUTATION; IN VIVO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

ANIMALS; CARCINOGENS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GUIDELINES AS TOPIC; HUMANS; MUTAGENS; MUTATION; NEOPLASMS; RISK ASSESSMENT; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

MUS; RATTUS;

EID: 46549089245     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2008.01.015     Document Type: Article

References (40)

1. Chan P.C., Haseman J.K., Prejean J.D., and Nyska A. Toxicology and carcinogenicity of riddelliine in rats and mice. Toxicol. Lett. 144 (2003) 295-311
2. ® rats. Environ. Mol. Mutagen. 37 (2001) 195-202
3. Cimino M.C. Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes. Environ. Mol. Mutagen. 47 (2006) 362-390
4. Clewell H.J., and Andersen M.E. Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. Crit. Rev. Toxicol. 34 5 (2004) 385-445
5. Cohen S.M., Meek M.E., Klaunig J.E., Patton D.E., and Fenner-Crisp P.A. The human relevance of information on carcinogenic modes of action: overview. Crit. Rev. Toxicol. 33 (2003) 581-589
6. Crump K. A new method for determining allowable daily intakes. Fundam. Appl. Toxicol. 4 (1984) 854-871
7. DeAngelo A.B., George M.H., and House D.E. Hepatocarcinogenicity in the male B6C3F1 mouse following a lifetime exposure to dichloroacetic acid in the drinking water: dose-response determination and modes of action. J. Toxicol. Environ. Health A 58 (1999) 485-507
8. Dearfield K.L., and Moore M.M. Use of genetic toxicology information for risk assessment. Environ. Mol. Mutagen. 46 (2005) 236-245
9. Dearfield K.L., Auletta A.E., Cimino M.C., and Moore M.M. Considerations in the U.S. Environmental Protection Agency's testing approach for mutagenicity. Mutat. Res. 258 (1991) 259-283
10. Dycaico M.J., Provost G.S., Kretz P.L., Ransom S.L., Moores J.C., and Short J.M. The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat. Res. 307 (1994) 461-478
11. Fu P.P., Siz Q., Lin G., and Chou M.W. Pyrrolizidone alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab. Rev. 36 (2004) 1-55
12. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
13. Hayashi H., Kondo H., Masumura K., Shindo Y., and Nohmi T. Novel transgenic rat for in vivo genotoxicity assays using 6-thioguanine and Spi- selection. Environ. Mol. Mutagen. 41 (2003) 253-259
14. Heddle J.A., Dean L., Nohmi T., Boerrigter M., Casciano D., Douglas G.R., Glickman B.W., Gorelick N.J., Mirsalis J.C., Martus H.-J., Skopek T.R., Thybaud V., Tindall K.R., and Yajima N. In vivo transgenic mutation assays. Environ. Mol. Mutagen. 35 (2000) 253-259
15. Heddle J.A., Martus H.J., and Douglas G.R. Treatment and sampling protocols for transgenic mutation assays. Environ. Mol. Mutagen. 41 (2003) 1-6
16. Hill K.A., Buettner V.L., Glickman B.W., and Sommer S.S. Spontaneous mutations in the Big Blue transgenic system are primarily mouse derived. Mutat. Res. 436 (1999) 11-19
17. Kavlock R.J., Schmid J.E., and Setzer Jr. R.W. A simulation study of the influence of study design on the estimation of benchmark doses for developmental toxicity. Risk Anal. 16 (1996) 399-410
18. Kirman C.R., Gargas M.L., Marsh G.M., Strother D.E., Klaunig J.E., Collins J.J., and Deskin R. Cancer dose-response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity. Regul. Toxicol. Pharmacol. 43 1 (2005) 85-103
19. Knudson A.G. Cancer genetics. Am. J. Med. Genet. 22 (2002) 96-102
20. Kodell R.L., and West R.W. Upper confidence limits on excess risk for quantitative responses. Risk Anal. 13 (1993) 177-182
21. Leavitt S.A., DeAngelo A.B., George M.H., and Ross J.A. Assessment of the mutagenicity of dichloroacetic acid in lacI transgenic B6C3F1 mouse liver. Carcinogenesis 18 (1997) 2101-2106
22. McKinzie P.B., Delongchamp R.R., Heflich R.H., and Parsons B.L. Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutat. Res. 489 (2001) 47-78
23. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., and Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33 (2003) 591-653
24. Mei N., Heflich R.H., Chou M.W., and Chen T. Mutations induced by the carcinogenic pyrrolizidine alkaloid riddelliine in the liver cII gene of transgenic Big Blue rats. Chem. Res. Toxicol. 17 (2004) 814-818
25. Mei N., Chou M.W., Fu P.P., Heflich R.H., and Chen T. Differential mutagenicity of riddelliine in liver endothelial and parenchymal cells of transgenic big blue rats. Cancer Lett. 215 (2004) 151-158
26. Melnick R.L., Huff J., Barrett J.C., Maronpot R.R., Lucier G., and Portier C.J. Cell proliferation and chemical carcinogenesis: a symposium overview. Mol. Carcinog. 7 (1993) 135-138
27. Moore M.M., and Harrington-Brock K. Mutagenicity of trichloroethylene and its metabolites: implications for the risk assessment of trichloroethylene. Environ. Health Perspect. 108 Suppl 2 (2000) 215-223
28. National Toxicology Program. Toxicology and carcinogenesis studies of riddelliine (CAS No 23246-96-0) in F344/N rats and B6C3F1 mice (gavage studies). Natl. Toxicol. Program Technol. Rep. Ser. 508 (2003) 1-280
29. ® mouse with those in tumor related genes in rodents. Carcinogenesis 18 (2001) 745-748
30. Singh V.K., Ganesh L., Cunningham M.L., and Shane B.S. Comparison of the mutant frequencies and mutation spectra of three non-genotoxic carcinogens, oxazepam, phenobarbital, and Wyeth 14,643, at the lambda cII locus in Big Blue transgenic mice. Biochem. Pharmacol. 62 (2001) 685-692
31. Shipp A., Lawrence G., Gentry R., McDonald T., Bartow H., Bounds J., Macdonald N., Clewell H., Allen B., and Van Landingham C. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects. Crit. Rev. Toxicol. 36 6-7 (2006) 481-608
32. TM B6C3F1 mice. Environ. Mol. Mutagen. 26 (1995) 9-15
33. Thilly W. Have environmental mutagens caused oncomutations in people?. Nat. Genet. 34 3 (2003) 255-259
34. Thybaud V., Dean S., Nohmi T., de Boer J., Douglas G.R., Glickman B.W., Gorelick N.J., Heddle J.A., Heflich R.H., Lambert I., Martus H.J., Mirsalis J.C., Suzuki T., and Yajima N. In vivo transgenic mutation assays. Mutat. Res. 540 (2003) 141-151
35. U.S. EPA, 2000. Benchmark Dose Technical Guidance Document. External Review Draft. EPA/630/R-00/001, October 2000.
36. U.S. EPA, 2003. EPA's Benchmark Dose Software (BMDS), Version 1.4.1. Available from: .
37. U.S. EPA, 2005. Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001B, March 2005.
38. U.S. EPA, 2006. U.S. Environmental Protection Agency 'Integrated Risk Information System (IRIS)'. Available from: .
39. U.S. EPA, 2007. Framework for Determining a Mutagenic Mode of Action for Carcinogenicity. Available from: .
40. Zhang X.B., Felton J.S., Tucker J.D., Urlando C., and Heddle J.A. Intestinal mutagenicity of two carcinogenic food mutagens in transgenic mice: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and amino(α)carboline. Carcinogenesis 17 (1996) 2259-2265